{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-015846","form_type":"8-K","ticker":"AIXC","cik":"0001460702","company_name":"AIxCrypto Holdings, Inc.","filed_at":"2025-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.029416+00:00","generated_at":"2026-05-17T05:23:28.307731+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Qualigen Therapeutics appoints Kevin Chen as independent director effective Sept 26, 2025","bullets":["Kevin Chen, 47, appointed as independent director, effective immediately.","Chen serves as Chief Economist and CIO of Horizon Financial.","He holds board seats at CurrenC Group, Australian Oilseeds Investments, Scage Future, Capitan Investment.","Former board member of Infint Acquisition Corporation; adjunct professor at NYU.","Chen holds PhD in Finance from University of Lausanne, and BA from Renmin University."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-015846","json":"https://secwatch.observer/filing/0001493152-25-015846.json","markdown":"https://secwatch.observer/filing/0001493152-25-015846.md","text":"https://secwatch.observer/filing/0001493152-25-015846.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1460702/000149315225015846/0001493152-25-015846-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1460702/000149315225015846/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:23:28.307731+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}